FDA Signs Off Hoth Therapeutics' Trial Application For HT-001 For Skin Cancers

 

• The FDA has accepted the Investigational New Drug (IND) application for Hoth Therapeutics Inc's 
  HOTH+139.8%+ Free Alerts
   HT-001 therapeutic for rash and skin disorders associated with epidermal growth factor receptor (EGFR) inhibitor therapy. 
• EGFR inhibitors are critical therapeutic agents for the treatment of non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer, squamous-cell carcinoma of the head and neck, and breast cancer.
• "With no specific treatment currently approved for the treatment of skin toxicities associated with EGFRi therapies, this trial brings us one step closer to a new treatment option for underserved cancer patients," said Robb Knie, CEO of Hoth Therapeutics. 
• The company expects to begin the Phase 2a trial in Q1 of 2023.
• In October, Hoth Therapeutics announced Phase 1b trial data for BioLexa in adult patients with mild-to-moderate atopic dermatitis showing an improvement in disease severity.

https://www.benzinga.com/general/biotech/22/12/30225677/fda-signs-off-hoth-therapeutics-trial-application-for-ht-001-for-skin-cancers